Related references
Note: Only part of the references are listed.Resectability of Peritoneal Carcinomatosis: Learnings from a Prospective Cohort of 533 Consecutive Patients Selected for Cytoreductive Surgery
Kayvan Mohkam et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Spontaneous regression of tumour and the role of microbial infection - possibilities for cancer treatment
Petra Kucerova et al.
ANTI-CANCER DRUGS (2016)
Regional CAR-T cell infusions for peritoneal carcinomatosis are superior to systemic delivery
S. C. Katz et al.
CANCER GENE THERAPY (2016)
Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18
Zhifeng Ma et al.
CLINICAL CANCER RESEARCH (2016)
Reversing T-cell Dysfunction and Exhaustion in Cancer
Hassane M. Zarour
CLINICAL CANCER RESEARCH (2016)
Natural killer cells stimulated with PM21 particles expand and biodistribute in vivo: Clinical implications for cancer treatment
Jeremiah L. Oyer et al.
CYTOTHERAPY (2016)
The role of regional chemotherapy in the management of extremity soft tissue malignancies
H. G. Smith et al.
EJSO (2016)
L1 Cell Adhesion Molecule-Specific Chimeric Antigen Receptor-Redirected Human T Cells Exhibit Specific and Efficient Antitumor Activity against Human Ovarian Cancer in Mice
Hao Hong et al.
PLOS ONE (2016)
Evolving Immunotherapy Approaches for Renal Cell Carcinoma
Susanna A. Curtis et al.
CURRENT ONCOLOGY REPORTS (2016)
Liver myeloid-derived suppressor cells expand in response to liver metastases in mice and inhibit the anti-tumor efficacy of anti-CEA CAR-T
Rachel A. Burga et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2015)
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases
Steven C. Katz et al.
CLINICAL CANCER RESEARCH (2015)
Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review
T. R. van Oudheusden et al.
EJSO (2015)
Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators
Isabelle Le Mercier et al.
FRONTIERS IN IMMUNOLOGY (2015)
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
Mythili Koneru et al.
ONCOIMMUNOLOGY (2015)
Cancer Immunotherapy and Breaking Immune Tolerance: New Approaches to an Old Challenge
Amani Makkouk et al.
CANCER RESEARCH (2015)
Treatment of gastric peritoneal carcinomatosis by combining complete surgical resection of lesions and intraperitoneal immunotherapy using catumaxomab
Diane Goere et al.
BMC CANCER (2014)
Surgical Management of Bowel Obstruction in Patients with Peritoneal Carcinomatosis
Bahbak Shariat-Madar et al.
JOURNAL OF SURGICAL ONCOLOGY (2014)
Immunotherapy for solid tumors-a review for surgeons
Abdul Saied et al.
JOURNAL OF SURGICAL RESEARCH (2014)
Peritoneal carcinomatosis of gastrointestinal tumors: Where are we now?
Cem Terzi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2014)
Surgical Outcomes of Hyperthermic Intraperitoneal Chemotherapy Analysis of the American College of Surgeons National Surgical Quality Improvement Program
Mehraneh D. Jafari et al.
JAMA SURGERY (2014)
Impact of peritoneal carcinomatosis in the disease history of colorectal cancer management: a longitudinal experience of 2406 patients over two decades
A. G. Kerscher et al.
BRITISH JOURNAL OF CANCER (2013)
Intraperitoneal delivery of human natural killer cells for treatment of ovarian cancer in a mouse xenograft model
Melissa A. Geller et al.
CYTOTHERAPY (2013)
Multifaceted Therapeutic Targeting of Ovarian Peritoneal Carcinomatosis Through Virus-induced Immunomodulation
Shashi Gujar et al.
MOLECULAR THERAPY (2013)
Chimeric Antigen Receptor-Modified T Cells for Acute Lymphoid Leukemia
Stephan A. Grupp et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone
P. Wimberger et al.
ANNALS OF ONCOLOGY (2012)
Early- and Long-Term Outcome Data of Patients With Pseudomyxoma Peritonei From Appendiceal Origin Treated by a Strategy of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy
Terence C. Chua et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Serous ovarian carcinoma patients with high alpha-folate receptor had reducing survival and cytotoxic chemo-response
Yu-Li Chen et al.
MOLECULAR ONCOLOGY (2012)
Membrane-Bound IL-21 Promotes Sustained Ex Vivo Proliferation of Human Natural Killer Cells
Cecele J. Denman et al.
PLOS ONE (2012)
Oncolytic Virus-initiated Protective Immunity Against Prostate Cancer
Shashi A. Gujar et al.
MOLECULAR THERAPY (2011)
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
Maria R. Parkhurst et al.
MOLECULAR THERAPY (2011)
Chimeric Antigen Receptor-Modified T Cells in Chronic Lymphoid Leukemia
David L. Porter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Novel Monoclonal Antibodies for Cancer Treatment: The Trifunctional Antibody Catumaxomab (Removab (R))
Diane Seimetz
JOURNAL OF CANCER (2011)
The trifunctional antibody catumaxomab for the treatment of malignant ascites due to epithelial cancer: results of a prospective randomized phase II/III trial
Markus M. Heiss et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Reovirus Virotherapy Overrides Tumor Antigen Presentation Evasion and Promotes Protective Antitumor Immunity
Shashi A. Gujar et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Safety and immunologic effects of IL-15 administration in nonhuman primates
Carolina Berger et al.
BLOOD (2009)
Expansion of Highly Cytotoxic Human Natural Killer Cells for Cancer Cell Therapy
Hiroyuki Fujisaki et al.
CANCER RESEARCH (2009)
Autologous MUC1-specific Th1 effector cell immunotherapy induces differential levels of systemic TReg cell subpopulations that result in increased ovarian cancer patient survival
Mark J. Dobrzanski et al.
CLINICAL IMMUNOLOGY (2009)
High incidence of CTLA-4 AA (CT60) polymorphism in renal cell cancer
Jose M. Cozar et al.
HUMAN IMMUNOLOGY (2007)
Characterisation of the new EpCAM-specific antibody HO-3:: implications for trifunctional antibody immunotherapy of cancer
P. Ruf et al.
BRITISH JOURNAL OF CANCER (2007)
Effective relief of malignant ascites in patients with advanced ovarian cancer by a trifunctional anti-EpCAM x anti-CD3 antibody:: A phase I/II study
Alexander Burges et al.
CLINICAL CANCER RESEARCH (2007)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Long-term survival following treatment of pseudomyxoma peritonei - An analysis of surgical therapy
TJ Miner et al.
ANNALS OF SURGERY (2005)
Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: A multi-institutional study
O Glehen et al.
JOURNAL OF CLINICAL ONCOLOGY (2004)
CpG motifs: the active ingredient in bacterial extracts?
AM Krieg
NATURE MEDICINE (2003)
Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes
ME Dudley et al.
SCIENCE (2002)
MUC1-specific anti-tumor responses: molecular requirements for CD4-mediated responses
ML VanLith et al.
INTERNATIONAL IMMUNOLOGY (2002)
Indications for early postoperative intraperitoneal chemotherapy of advanced gastric cancer: Results of a prospective randomized trial
W Yu et al.
WORLD JOURNAL OF SURGERY (2001)
PD-L2 is a second ligand for PD-I and inhibits T cell activation
Y Latchman et al.
NATURE IMMUNOLOGY (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
